Related Experiment Video
Updated: Aug 14, 2026
Inducible and Reversible Dominant-negative (DN) Protein Inhibition
Published on: January 7, 2019
Subtractive cloning and characterization of DRAL, a novel LIM-domain protein down-regulated in rhabdomyosarcoma
M Genini1, P Schwalbe, F A Scholl
1Department of Pediatrics, University of Zürich, Switzerland.
Abstract:
A subtractive cloning procedure was used to characterize the molecular changes involved in transformation of normal myoblasts to rhabdomyosarcoma (RMS) cells. Here we describe the cloning of DRAL, a novel LIM-domain protein expressed in primary myoblasts but down-regulated in the RMS cell line RD. DRAL is a LIM-only protein with five LIM domains whereby one LIM domain consists only of the second half of the consensus motif. Interestingly, down-regulation of DRAL was not confined to the RD RMS cells, but was a phenomenon extended to other RMS cell lines of both embryonal and alveolar subtype, and to some breast cancer cell lines. Analysis of the expression pattern in normal human tissues revealed that DRAL is expressed at high levels in the heart, suggesting an important function in the specification of the terminally differentiated phenotype of heart muscle cells. Immunofluorescence studies using an antibody directed against recombinant DRAL localized the protein predominantly in the nucleus of cultured cells. On the basis of these results, we conclude that down-regulation of DRAL correlates with the tumor phenotype of RMS cells.
Insights
Down-regulation of the novel LIM-domain protein DRAL is observed in rhabdomyosarcoma (RMS) cells and some breast cancers. This finding suggests DRAL
Area of Science:
- Molecular biology
- Cell biology
- Cancer research
Background:
- Rhabdomyosarcoma (RMS) is a pediatric cancer originating from muscle progenitor cells.
- Understanding molecular changes during myoblast transformation to RMS is crucial for targeted therapies.
Purpose of the Study:
- To identify molecular alterations associated with the transformation of normal myoblasts into RMS cells.
- To clone and characterize novel genes involved in this cellular process.
Main Methods:
- Subtractive cloning to identify differentially expressed genes.
- Analysis of DRAL gene expression in RMS cell lines and normal human tissues.
- Immunofluorescence to determine DRAL protein localization.
Main Results:
- Cloning of DRAL, a novel LIM-domain protein, highly expressed in primary myoblasts but down-regulated in RD RMS cells.
- Down-regulation of DRAL observed across various RMS subtypes and some breast cancer cell lines.
- High DRAL expression in the heart suggests a role in cardiac muscle differentiation; nuclear localization in cultured cells.
Conclusions:
- Down-regulation of DRAL correlates with the development of the RMS tumor phenotype.
- DRAL may play a role in muscle cell differentiation and tumor suppression.
Related Concept Videos
01:23Negative Regulator Molecules
02:23Abnormal Proliferation
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...